NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS ANNOUNCEMENT. This announcement is an advertisement for the purposes of the Prospectus Regulation Rules of the Financial Conduct Authority ( FCA ) and is not a prospectus and not an offer of shares for sale in any jurisdiction, including in or into Australia, Canada, Japan or the United States. Neither this announcement, nor anything contained herein, shall form the basis of, or be relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. Investors should not subscribe for or purchase any shares referred to in this announcement except solely on the basis of the information contained in a prospectus in its final form (together with any supplementary prospectus, if relevant, t
Founded in 1987, Etalon Group is one of the largest development and construction companies in Russia. The Company focuses on middle class residential real estate in the Moscow and St Petersburg metropolitan areas. With a more than 30-year history, Etalon Group has one of the longest and most successful track records in the Russian real estate industry. Since its foundation, Etalon Group has commissioned 7.5 million sqm of real estate. The Company is vertically integrated, which helps it to control costs, quality and timing, as well as maintain best-in-class profitability. Etalon Group employs over 5,000 people, and its nationwide sales and marketing network covers 59 Russian cities.
IMPORTANT INFORMATION
This press release includes forward-looking statements . All statements other than statements of historical facts included in this press release, including, without limitation, those regarding Air France-KLM’s financial position, business strategy, plans and objectives of management for future operations, are forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Air France-KLM, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding Air France-KLM’s present and future business strategies and the environment in which Air France-KLM will operate in the future. Additional factors could cause actual results, performance or achievements to differ mat
Zhaoke Ophthalmology is an ophthalmic pharmaceutical company dedicated to the research, development and commercialization of therapies that address significant unmet medical needs in China. Leveraging its deep domain expertise while designing the pipeline, the Company has initially placed strategic emphasis on five major ophthalmic indications in China in terms of market potential, including dry eye disease, or DED, wet age-related macular degeneration, or wAMD, diabetic macular edema, or DME, myopia and glaucoma. Up to now, the Company has built a comprehensive ophthalmic drug pipeline of 25 candidates that covers most major ocular indications affecting the front and the back of the eye, through either in-house development or in-licensing.
TodayIR: Zhaoke Ophthalmology Limited (6622.HK) Announces Proposed Listing on the Main Board of SEHK Final DJ EQS-News: Zhaoke Ophthalmology Limited (6622.HK) Announces Proposed Listing on the Main Board of SEHK Final EQS-News / 16/04/2021 / 11:26 UTC+8 Zhaoke Ophthalmology Limited (6622.HK) Launches Its HKPO with 8 Cornerstone Investors to Fuel Its Future Growth (April 16, 2021, Hong Kong) Zhaoke Ophthalmology Limited ( Zhaoke Ophthalmology or the Company ; stock code: 6622), an ophthalmic pharmaceutical company dedicated to the research, development and commercialization of therapies that address significant unmet medical needs, announced the proposed listing of its shares on the Main Board of The Stock Exchange of Hong Kong Limited ( SEHK ) today. Goldman Sachs (Asia) L.L.C., and Jefferies Hong Kong Limited are the Joint Sponsors, Joint Representatives, Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers.